Topics

FDA grants Fast Track status to Akari's nomacopan for HSCT-TMA

06:40 EDT 15 Aug 2019 | SmartBrief

The FDA has designated Fast Track status to Akari Therapeutics' Coversin, or nomacopan, indicated for pediatric patients with -More

Original Article: FDA grants Fast Track status to Akari's nomacopan for HSCT-TMA

NEXT ARTICLE

More From BioPortfolio on "FDA grants Fast Track status to Akari's nomacopan for HSCT-TMA"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...